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reserved.Using kitchen scales, carefully weight out 4 kg of rice and
pour it into a deep saucepan. Now put your hands into the rice
and let the grains run between your ﬁngers. Contemplate care-
fully each grain. The number of grains (about 140,000) is
approximately the number of lives that could be saved each
year world-wide if all hospitalized trauma patients with signif-
icant bleeding were treated with tranexamic acid (TXA) within
3 h of injury. TXA is cheap and widely available. All that is
needed to reap these human beneﬁts is that doctors use it.
That TXA is a potent inhibitor of ﬁbrinolysis which was
ﬁrst reported by Okamoto and Okamoto in The Keio Journal
of Medicine in September 1962.1 Since then TXA has been
widely used to treat heavy menstrual bleeding and to reducec.uk, collette.barrow@Lshtm.
ersity Faculty of Medicine.
. All rights reserved.
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lsevierblood loss in elective surgery where it reduces blood transfu-
sion by about one-third.2 The CRASH-2 collaborators
hypothesized that TXA might also reduce bleeding in trauma
patients. The CRASH-2 trial was a UK government funded
randomized trial of the effects of the early administration of
TXA on death, vascular occlusive events and blood transfu-
sion in bleeding trauma patients.
A total of 20,211 adults with signiﬁcant traumatic bleeding
were randomized to receive TXA or matching placebo, with
99.6% follow-up. The risk of death due to bleeding was signif-
icantly reduced with TXA. If TXA is given within 3 h of injury,
it reduces the risk of bleeding to death by nearly one-third (rel-
ative risk = 0.72 [95%CI 0.63–0.83], p< 0.001). All cause
mortality was also signiﬁcantly reduced.3,4 The large numbers
of patients studied in a wide range of different health care set-
tings help these results to be generalized widely. On the basis of
the results of the CRASH-2 trial, TXA has been included in
the WHO list of essential medicines.5 Giving TXA to bleeding
trauma patients within 3 h of the injury could save over
100,000 lives per year world-wide. Giving TXA to bleeding
trauma patients is highly cost effective in high, middle and
low income countries.6 It is essential that all doctors who treat
trauma patients are aware of the results of the CRASH-2 trial.
TXA should be given to all adults with signiﬁcant haemor-
rhage (SBP < 90, HR> 110) or those considered by the clini-
cian to be at risk for signiﬁcant haemorrhage. Because the
2 I. Robertseffect of tranexamic acid on death due to bleeding depends
importantly on the time interval between the injury and the on-
set of treatment it should be given as early as possible and
within 3 or 4 h of the injury as it is unlikely to be effective if
given later than this.
References
1. Okamoto S, Okamoto U. Amino-methyl-cyclohexane-carbolic acid:
AMCHA. A new potent inhibitor of ﬁbrinolysis. Keio J Med
1962;11:105–15.
2. Henry DA, Carless PA, Moxey AJ, et al. Anti-ﬁbrinolytic use for
minimising perioperative allogeneic blood transfusion. Cochrane
Database Syst Rev 2007;4:CD001886.3. The CRASH-2 Collaborators. Effects of tranexamic acid on death,
vascular occlusive events, and blood transfusion in trauma patients
with signiﬁcant haemorrhage (CRASH-2): a randomized, placebo-
controlled trial. Lancet 2010;376:23–32.
4. The CRASH-2 Collaborators. The importance of early treatment
with tranexamic acid in bleeding trauma patients: an exploratory
analysis of the CRASH-2 randomized controlled trial. Lancet
2011;377:1096–101.
5. <http://www.who.int/selection_medicines/committees/expert/18/
en/index.html>.
6. Guerriero C, Cairns J, Perel P, Shakur H, Roberts I, et al. Cost-
effectiveness analysis of administering tranexamic acid to bleeding
trauma patients using evidence from the CRASH-2 trial. PLoS
ONE 2011;6(5):e18987. doi:10.1371/journal.pone.001898.
